Q3 2021 13F Holders as of 30 Sep 2021
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
382,523,969
-
Total 13F shares
-
792,063,021
-
Share change
-
+792,032,864
-
Total reported value
-
$9,177,441,180
-
Put/Call ratio
-
56%
-
Price per share
-
$11.59
-
Number of holders
-
122
-
Value change
-
+$9,177,093,199
-
Number of buys
-
120
Institutional Holders of RECURSION PHARMACEUTICALS, INC. - Common Stock (DNA) as of Q3 2021
As of 30 Sep 2021,
RECURSION PHARMACEUTICALS, INC. - Common Stock (DNA) was held by
122 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
792,063,021 shares.
The largest 10 holders included
VIKING GLOBAL INVESTORS LP, GENERAL ATLANTIC, L.P., BAILLIE GIFFORD & CO, Senator Investment Group LP, Anchorage Capital Group, L.L.C., ARK Investment Management LLC, MORGAN STANLEY, FRANKLIN RESOURCES INC, Casdin Capital, LLC, and Telemark Asset Management, LLC.
This page lists
122
institutional shareholders reporting positions in this security
for the Q3 2021 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.